APA (7th ed.) Citation

HS, H., P, C., M, W., EP, M., D, C., PJ, O., . . . AB, B. (2024). Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: Randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). Journal of the National Cancer Institute, 116(9), 1487. https://doi.org/10.1093/jnci/djae114

Chicago Style (17th ed.) Citation

HS, Hochster, et al. "Combining Antivascular Endothelial Growth Factor and Anti-epidermal Growth Factor Receptor Antibodies: Randomized Phase II Study of Irinotecan and Cetuximab With/without Ramucirumab in Second-line Colorectal Cancer (ECOG-ACRIN E7208)." Journal of the National Cancer Institute 116, no. 9 (2024): 1487. https://doi.org/10.1093/jnci/djae114.

MLA (9th ed.) Citation

HS, Hochster, et al. "Combining Antivascular Endothelial Growth Factor and Anti-epidermal Growth Factor Receptor Antibodies: Randomized Phase II Study of Irinotecan and Cetuximab With/without Ramucirumab in Second-line Colorectal Cancer (ECOG-ACRIN E7208)." Journal of the National Cancer Institute, vol. 116, no. 9, 2024, p. 1487, https://doi.org/10.1093/jnci/djae114.